Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=24578503
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Blood
2014[Apr]; 123
(16
): 2470-7
PMID24578503
show ga
Unconjugated monoclonal antibodies that target hematopoietic differentiation
antigens have been developed to treat hematologic malignancies. Although some of
these have activity against chronic lymphocytic leukemia and hairy cell leukemia,
in general, monoclonal antibodies have limited efficacy as single agents in the
treatment of leukemia. To increase their potency, the binding domains of
monoclonal antibodies can be attached to protein toxins. Such compounds, termed
immunotoxins, are delivered to the interior of leukemia cells based on antibody
specificity for cell surface target antigens. Recombinant immunotoxins have been
shown to be highly cytotoxic to leukemic blasts in vitro, in xenograft model
systems, and in early-phase clinical trials in humans. These agents will likely
play an increasing role in the treatment of leukemia.
free
free
free
